<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37147021</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Glomerular mTORC1 activation was associated with podocytes to endothelial cells communication in lupus nephritis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000896</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000896</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study was initiated to evaluate the mammalian target of the rapamycin (mTOR) signalling pathway involved in renal endothelial-podocyte crosstalk in patients with lupus nephritis (LN).</AbstractText><AbstractText Label="METHODS">We compared the kidney protein expression patterns of 10 patients with LN with severe endothelial-podocyte injury and 3 patients with non-severe endothelial-podocyte injury on formalin-fixed paraffin-embedded kidney tissues using label-free liquid chromatography-mass spectrometry for quantitative proteomics analysis. Podocyte injury was graded by foot process width (FPW). The severe group was referred to patients with both glomerular endocapillary hypercellularity and FPW &gt;1240 nm. The non-severe group included patients with normal endothelial capillaries and FPW in the range of 619~1240 nm. Gene Ontology (GO) enrichment analyses were performed based on the protein intensity levels of differentially expressed proteins in each patient. An enriched mTOR pathway was selected, and the activation of mTOR complexes in renal biopsied specimens was further verified in 176 patients with LN.</AbstractText><AbstractText Label="RESULTS">Compared with those of the non-severe group, 230 proteins were upregulated and 54 proteins were downregulated in the severe group. Furthermore, GO enrichment analysis showed enrichment in the 'positive regulation of mTOR signalling' pathway. The glomerular activation of mTOR complex 1 (mTORC1) was significantly increased in the severe group compared with the non-severe group (p=0.034), and mTORC1 was located in podocytes and glomerular endothelial cells. Glomerular activation of mTORC1 was positively correlated with endocapillary hypercellularity (r=0.289, p&lt;0.001) and significantly increased in patients with both endocapillary hypercellularity and FPW &gt;1240 nm (p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Glomerular mTORC1 was highly activated in patients with both glomerular endocapillary hypercellularity and podocyte injury, which might be involved in podocytes to endothelial cells communication in lupus nephritis.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaotian</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-0142-0782</Identifier><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zhaomin</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-9029-7252</Identifier><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Mo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5372-0106</Identifier><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China tanying@bjmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Peking University International Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3060-6233</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Peking University International Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050199" MajorTopicYN="Y">Podocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37147021</ArticleId><ArticleId IdType="pmc">PMC10163597</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000896</ArticleId><ArticleId IdType="pii">10/1/e000896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anders H-J, Saxena R, Zhao M-H, et al. . Lupus nephritis. Nat Rev Dis Primers 2020;6:7. 10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Haas M, Glassock R, et al. . Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 2017;13:483&#x2013;95. 10.1038/nrneph.2017.85</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.85</ArticleId><ArticleId IdType="pubmed">28669995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, et al. . Revision of the International Society of nephrology/renal pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of health activity and chronicity indices. Kidney Int 2018;93:789&#x2013;96. 10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-H, Yu F, Tan Y, et al. . Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions [J]. Kidney International 2013;83:715&#x2013;23. 10.1038/ki.2012.409</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.409</ArticleId><ArticleId IdType="pubmed">23302713</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D, Wu L, Wang F, et al. . The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013;15:R12. 10.1186/ar4142</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4142</ArticleId><ArticleId IdType="pmc">PMC3672792</ArticleId><ArticleId IdType="pubmed">23320601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yu F, Song D, et al. . Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford) 2014;53:1235&#x2013;44. 10.1093/rheumatology/ket491</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket491</ArticleId><ArticleId IdType="pubmed">24599917</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Tan Y, Wang Y, et al. . The associations of endothelial and podocyte injury in proliferative lupus nephritis: from observational analysis to in vitro study. Lupus 2019;28:347&#x2013;58. 10.1177/0961203319828509</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319828509</ArticleId><ArticleId IdType="pubmed">30755145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebefors K, Wiener RJ, Yu L, et al. . Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells. Kidney Int 2019;96:957&#x2013;70. 10.1016/j.kint.2019.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.05.007</ArticleId><ArticleId IdType="pmc">PMC7200072</ArticleId><ArticleId IdType="pubmed">31402170</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Lest NA, Bakker AE, Dijkstra KL, et al. . Endothelial endothelin receptor A expression is associated with podocyte injury and oxidative stress in patients with focal segmental glomerulosclerosis. Kidney Int Rep 2021;6:1939&#x2013;48. 10.1016/j.ekir.2021.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.04.013</ArticleId><ArticleId IdType="pmc">PMC8258598</ArticleId><ArticleId IdType="pubmed">34307988</ArticleId></ArticleIdList></Reference><Reference><Citation>Daehn I, Casalena G, Zhang T, et al. . Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014;124:1608&#x2013;21. 10.1172/JCI71195</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI71195</ArticleId><ArticleId IdType="pmc">PMC3973074</ArticleId><ArticleId IdType="pubmed">24590287</ArticleId></ArticleIdList></Reference><Reference><Citation>van Aanhold CCL, Bos M, Mirabito Colafella KM, et al. . n.d. Thrombomodulin is upregulated in the kidneys of women with pre-eclampsia. Sci Rep;11. 10.1038/s41598-021-85040-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85040-9</ArticleId><ArticleId IdType="pmc">PMC7952396</ArticleId><ArticleId IdType="pubmed">33707524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewell JL, Russell RC, Guan K-L. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013;14:133&#x2013;9. 10.1038/nrm3522</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3522</ArticleId><ArticleId IdType="pmc">PMC3988467</ArticleId><ArticleId IdType="pubmed">23361334</ArticleId></ArticleIdList></Reference><Reference><Citation>Weichhart T, Hengstschl&#xe4;ger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol 2015;15:599&#x2013;614. 10.1038/nri3901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3901</ArticleId><ArticleId IdType="pmc">PMC6095456</ArticleId><ArticleId IdType="pubmed">26403194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. Journal of the American Society of Nephrology 2009;20:2493&#x2013;502. 10.1681/ASN.2008111186</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008111186</ArticleId><ArticleId IdType="pubmed">19875810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantus D, Rogers NM, Grahammer F, et al. . Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol 2016;12:587&#x2013;609. 10.1038/nrneph.2016.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.108</ArticleId><ArticleId IdType="pmc">PMC6553645</ArticleId><ArticleId IdType="pubmed">27477490</ArticleId></ArticleIdList></Reference><Reference><Citation>Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9&#x2013;22. 10.1016/j.ccr.2007.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2007.05.008</ArticleId><ArticleId IdType="pubmed">17613433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Z, Tan Y, Tao J, et al. . Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis. Rheumatology (Oxford) 2022;61:3830&#x2013;40. 10.1093/rheumatology/keac037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac037</ArticleId><ArticleId IdType="pmc">PMC9608003</ArticleId><ArticleId IdType="pubmed">35040950</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimarchi H, Barratt J, Cattran DC, et al. . Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification Working group. Kidney International 2017;91:1014&#x2013;21. 10.1016/j.kint.2017.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.02.003</ArticleId><ArticleId IdType="pubmed">28341274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang MH, Socher SA, Larson MG, et al. . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Care Res
1989;32:1107&#x2013;18. 10.1002/anr.1780320909
Available: http://doi.wiley.com/10.1002/anr.v32:9</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anr.1780320909</ArticleId><ArticleId IdType="pubmed">2775320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, et al. . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on prognosis studies in SLE. Arthritis Rheum 1992;35:630&#x2013;40. 10.1002/art.1780350606</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-Y, Ding Y, Li L-L, et al. . Proteomic profiling of kidney samples in patients with pure membranous and proliferative lupus nephritis. Lupus 2022;31:837&#x2013;47. 10.1177/09612033221094711</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221094711</ArticleId><ArticleId IdType="pubmed">35446734</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaud G, Bienaim&#xe9; F, Tabarin F, et al. . Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303&#x2013;12. 10.1056/NEJMoa1312890</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312890</ArticleId><ArticleId IdType="pubmed">25054716</ArticleId></ArticleIdList></Reference><Reference><Citation>Anandapadamanaban M, Masson GR, Perisic O, et al. . Architecture of human RAG GTPase heterodimers and their complex with mTORC1. Science 2019;366:203&#x2013;10. 10.1126/science.aax3939</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax3939</ArticleId><ArticleId IdType="pmc">PMC6795536</ArticleId><ArticleId IdType="pubmed">31601764</ArticleId></ArticleIdList></Reference><Reference><Citation>Avihingsanon Y, Benjachat T, Tassanarong A, et al. . Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney International 2009;75:1340&#x2013;8. 10.1038/ki.2009.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2009.75</ArticleId><ArticleId IdType="pubmed">19295501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshibayashi M, Kume S, Yasuda-Yamahara M, et al. . Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes. Biochemical and Biophysical Research Communications 2020;525:319&#x2013;25. 10.1016/j.bbrc.2020.02.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.02.088</ArticleId><ArticleId IdType="pubmed">32089264</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaomiao W, Chunhua L, Xiaochen Z, et al. . Autophagy is involved in regulating VEGF during high-glucose-induced podocyte injury. Mol Biosyst 2016;12:2202&#x2013;12. 10.1039/c6mb00195e</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c6mb00195e</ArticleId><ArticleId IdType="pubmed">27138352</ArticleId></ArticleIdList></Reference><Reference><Citation>Avihingsanon Y, Phumesin P, Benjachat T, et al. . Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006;69:747&#x2013;53. 10.1038/sj.ki.5000132</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5000132</ArticleId><ArticleId IdType="pubmed">16518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro C, Candia-Z&#xfa;&#xf1;iga L, Silveira LH, et al. . Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002;11:21&#x2013;4. 10.1191/0961203302lu131oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203302lu131oa</ArticleId><ArticleId IdType="pubmed">11898914</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain A, Khadka A, Ehrlicher A, et al. . Substrate stiffening promotes VEGF-A functions via the PI3K/Akt/mTOR pathway. Biochem Biophys Res Commun 2022;586:27&#x2013;33. 10.1016/j.bbrc.2021.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.11.030</ArticleId><ArticleId IdType="pmc">PMC8785232</ArticleId><ArticleId IdType="pubmed">34823219</ArticleId></ArticleIdList></Reference><Reference><Citation>Eremina V, Cui S, Gerber H, et al. . Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. Journal of the American Society of Nephrology 2006;17:724&#x2013;35. 10.1681/ASN.2005080810</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2005080810</ArticleId><ArticleId IdType="pubmed">16436493</ArticleId></ArticleIdList></Reference><Reference><Citation>Eremina V, Jefferson JA, Kowalewska J, et al. . Vegf inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129&#x2013;36. 10.1056/NEJMoa0707330</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0707330</ArticleId><ArticleId IdType="pmc">PMC3030578</ArticleId><ArticleId IdType="pubmed">18337603</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoki K, Mori H, Wang J, et al. . Mtorc1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011;121:2181&#x2013;96. 10.1172/JCI44771</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44771</ArticleId><ArticleId IdType="pmc">PMC3104745</ArticleId><ArticleId IdType="pubmed">21606597</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;del M, Hartleben B, Herbach N, et al. . Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011;121:2197&#x2013;209. 10.1172/JCI44774</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44774</ArticleId><ArticleId IdType="pmc">PMC3104746</ArticleId><ArticleId IdType="pubmed">21606591</ArticleId></ArticleIdList></Reference><Reference><Citation>Caza T, Wijewardena C, Al-rabadi L, et al. . Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis. Translational Research 2022;245:55&#x2013;81. 10.1016/j.trsl.2022.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2022.03.004</ArticleId><ArticleId IdType="pmc">PMC9240418</ArticleId><ArticleId IdType="pubmed">35288362</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieling PA, Porcelli SA, Duong BT, et al. . Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. The Journal of Immunology 2000;165:5338&#x2013;44. 10.4049/jimmunol.165.9.5338</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.9.5338</ArticleId><ArticleId IdType="pubmed">11046069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Z-W, Kelly R, Winans T, et al. . Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet 2018;391:1186&#x2013;96. 10.1016/S0140-6736(18)30485-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30485-9</ArticleId><ArticleId IdType="pmc">PMC5891154</ArticleId><ArticleId IdType="pubmed">29551338</ArticleId></ArticleIdList></Reference><Reference><Citation>Piranavan P, Perl A. Improvement of renal and non-renal SLE outcome measures on sirolimus therapy-a 21-year follow-up study of 73 patients. Clin Immunol 2021;229:108781. 10.1016/j.clim.2021.108781</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108781</ArticleId><ArticleId IdType="pmc">PMC9240417</ArticleId><ArticleId IdType="pubmed">34144197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DY, Ma MK, Tang CS, et al. . Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton)
2012;17:676&#x2013;80. 10.1111/j.1440-1797.2012.01646.x
Available: http://doi.wiley.com/10.1111/nep.2012.17.issue-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1797.2012.01646.x</ArticleId><ArticleId IdType="pubmed">22817609</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia M, Stabilini A, Migliavacca B, et al. . Rapamycin promotes expansion of functional CD4+CD25+FoxP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006;177:8338&#x2013;47. 10.4049/jimmunol.177.12.8338</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.12.8338</ArticleId><ArticleId IdType="pubmed">17142730</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>